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ABSTRACT
Objective: The aim of this study was to
investigate the strength and role of thera-
peutic alliance in a trial comparing Cogni-
tive Behavioral Therapy for anorexia
nervosa (CBT-AN) and Specialist Support-
ive Clinical Management for the treat-
ment of severe and enduring AN (SE-AN).
Method: Participants were 63 adult
females with SE-AN presenting to an out-
patient, multisite randomized controlled
trial conducted at two clinical sites. Partic-
ipants completed measures assessing
their perception of the quality of the
therapeutic relationship, eating disorder
(ED) symptomatology, and depressive
symptomatology.
Results: Beyond the effect of early treat-
ment change and treatment assignment,
early therapeutic alliance was a signifi-
cant predictor of Restraint and Shape
Concern at follow-up (ps < .02). Late
therapeutic alliance was a significant pre-
dictor of weight change, depressive symp-
tomatology, and ED symptomatology at
end of treatment and follow-up (ps <
.008), with the exception of Shape Con-
cern at follow-up (p5 .07).
Discussion: The results suggest that
therapeutic alliance can be effectively
established in the treatment of SE-AN
and may be relevant for treatment
response, particularly in late treatment,
on some aspects of ED and depressive
symptomatology. VC 2013 Wiley Periodi-
cals, Inc.
Keywords: therapeutic alliance;
anorexia nervosa; cognitive behav-
ioral therapy; specialist supportive
clinical management
(Int J Eat Disord 2013; 46:783–789)
Introduction
Severe and enduring anorexia nervosa (SE-AN),
defined as meeting criteria for AN for at least 7
years, is a public health concern as it creates a sub-
stantial burden in terms of morbidity, mortality,
suffering, and cost.1–9 Although there is promising
evidence for the efficacy of family-based treatment
for adolescents with AN,10 there is little evidence
for an empirically supported and effective treat-
ment for adults with SE-AN.2 This may be due to
high dropout rates in treatment studies related
to the misalignment of treatment aims for
recovery and patient readiness for change and
recovery.2,11
To address this dissonance in the treatment of
SE-AN, Touyz et al. conducted a randomized con-
trolled trial (RCT) with two treatments adapted to
more closely align with the aims of patients with
SE-AN such that weight gain was not a main goal
of treatment. A retention rate of 85% was achieved
at post-treatment, and significant improvements
were reported on the majority of outcome meas-
ures. The authors postulated that the findings are
related to a positive patient response to a broader
focus of treatment.12 Although these findings are
promising, more research is necessary to identify
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and better understand factors that influence out-
come in the treatment of SE-AN.
One possible factor is therapeutic alliance, which
refers to the relationship bond that can develop
between a client and therapist through collabora-
tive work and mutual trust in establishing and
reaching treatment goals.13 Therapeutic alliance
has been shown to predict outcomes in therapy
across a wide variety of disorders and treatment
modalities.14,15 Therapeutic alliance has been
shown to be effectively established in the treatment
of adults and adolescents with eating disorders
(EDs), yet its role in treatment outcome for ED
populations has been mixed.16–19 To our knowl-
edge, the role of therapeutic alliance in treatment
outcome for adults with SE-AN has not been
investigated.
The primary aim of this study is to fill this gap in
the literature by comparing the strength and role of
therapeutic alliance in a trial comparing Cognitive
Behavioral Therapy for AN (CBT-AN) and Specialist
Supportive Clinical Management (SSCM) for the
treatment of SE-AN. We hypothesized that there
would be no significant difference in strength of
therapeutic alliance between the two interventions
throughout treatment. We also hypothesized that
both early and late therapeutic alliance would pre-
dict positive treatment outcomes (e.g., ED severity
and depressive symptoms) at end of treatment and
follow-up, with the exception of weight gain, as
weight gain was not mandated in either treatment.
Method
This study is a secondary analysis of data from a RCT
conducted at two clinical sites (the University of Sydney
and St. George’s Hospital, University of London) and a
Data and Coordinating Center (the University of Chi-
cago) comparing the efficacy of CBT-AN and SSCM for a
cohort of adults with SE-AN. Specific treatment effects
have been analyzed and are reported in the main out-
come article.12 In the RCT, participants received 30 3 50-
min individual treatment sessions provided over a period
of 8 months in an outpatient setting.
Participants
Recruitment of participants occurred from July 2007 to
November 2010 through advertising to clinics treating
EDs, clinicians, and generic websites (see Supporting
Information Fig. S1).
Participants were eligible for RCT if they met the Diag-
nostic and Statistical Manual for Mental Disorders, 4th
Edition, Text Revision (DSM-IV-TR)20 criteria for AN,
excluding criterion D (amenorrhea); had an illness
duration of at least 7 years; were at least 18 years of age;
and were female. Exclusion criteria included presenting
with a current manic episode or psychosis; current
alcohol or substance abuse or dependence; significant
current medical or neurological illness (including seizure
disorder), with the exception of nutrition-related altera-
tions that are impacted by weight; current engagement
in psychotherapy and being unwilling to suspend such
treatment for the duration of their participation in the
study; and plans to move beyond commuting distance
for the study site in the following 12 months or not living
within commuting distance to the study site.
In compliance with the Institutional Review Boards of
all three sites, participants completed written informed
consent prior to assessment.
Treatments
Participants were randomly assigned to either CBT or
SSCM by a biostatistician in the Data and Coordinating
Center at the University of Chicago, independent from
either intervention sites. Randomization was conducted
using Ephron’s biased coin approach, stratified within
sites by subtype of illness (restrictive and binge–purge)
and psychiatric medication status. To minimize therapist
effects, three clinical psychologists with prior experience
treating EDs in adults acted as therapists for both the
CBT and SSCM conditions. All therapists attended two 2-
day in-person workshops for training in the manualized
treatments. All therapists treated pilot cases using each
treatment before being assigned randomized cases and
were supervised by senior clinicians throughout the
duration of the trial. Treatment occurred in outpatient
settings at the University of Sydney and St. George’s
Hospital, University of London. Both treatments involved
30 individual treatment sessions provided over 8 months.
Cognitive Behavioral Therapy-AN. CBT-AN is based on
the protocol developed by Pike et al.21 that focuses on
the cognitive and behavioral disturbances associated
with the main features of AN, as well as more global
issues related to the disorder, including motivational and
schema-based work. CBT-AN has four phases of treat-
ment. Phase I provides specific strategies for the start of
treatment, addressing issues related to motivation, and
orienting patients to the CBT process. Phase II then
focuses on strategies for addressing weight gain, as well
as cognitive distortions and behavioral disturbances
associated with eating and weight for the patient. Phase
III expands the focus of treatment to schema-based work
that addresses relevant issues that are outside of the spe-
cific domain of eating and weight. Phase IV focuses on
reviewing the therapy process, consolidating gains, and
preparing the patient to continue the work of CBT-AN
independently post-treatment. For this trial, CBT-AN was
modified to reflect a shift in treatment goals. Specifically,
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treatment goals were set collaboratively, and weight gain
was encouraged but not identified as the primary focus
of the treatment (although medical safety was monitored
and required to remain in the study).
Specialist Supportive Clinical Management. SSCM
combines features of clinical management and support-
ive psychotherapy.22,23 Supportive psychotherapy aims to
assist the patient through use of praise, advice, and reas-
surance. Clinical management includes support and psy-
choeducation while fostering a therapeutic relationship
with the intent of increasing adherence to treatment.
Goals are set in a collaborative manner and “target” EDs
and other symptoms to be a focus of therapy. Similarly to
CBT-AN, SSCM was modified for this trial such that
weight gain was not the primary treatment goal; instead,
patients were encouraged to make changes to improve
their quality of life and physical well-being. The rationale
for this emphasis in treatment is that efforts to aid indi-
viduals in improving quality of life will further motivate
and enable them to make progress on their core ED
pathology as well.
Physical Assessment
To calculate body mass index (BMI 5 kg=m2), weight
and height of the participants were measured by a
trained research assistant using a calibrated digital or
balance-beam scale and stadiometer, respectively. All
patients were weighed in light indoor clothing, without
shoes.
Measures
The Helping Relationships Questionnaire. The Helping
Relationships Questionnaire (HRQ)24 is an 11-item self-
report questionnaire measuring the quality of the thera-
pist–patient relationship from the patient’s perspective.
The HRQ was administered at Week 2, mid-treatment,
and end of treatment. Higher total scores reflect greater
therapeutic alliance. Examples of questions include “I
believe that my therapist is helping me” and “I feel I am
working together with the therapist in a joint effort.”
Items for the HRQ are rated on a 6-point Likert scale
ranging from 23 (strongly feel it is not true) to 13
(strongly feel it is true). Total scores, computed by sum-
ming all items, range from 233 to 33. Participant
responses with missing items on the HRQ were excluded
from analyses involving HRQ total scores. The HRQ has
strong psychometrics and has been shown to correlate
with treatment outcome.25,26
The Eating Disorder Examination. The Eating Disorder
Examination (EDE)27 is a semistructured investigator-
based interview measuring cognitive and behavioral
symptoms related to ED. The EDE was used to generate
DSM-IV-TR diagnoses for an ED and to assess the sever-
ity of ED symptomatology. Subscales include Weight
Concern, Shape Concern, Eating Concern, and Restraint.
Global scores reflect the overall severity of ED symptoms.
The EDE was administered at baseline, mid-treatment,
end of treatment, and 6 and 12 months post-treatment.
The EDE has demonstrated good reliability and
validity.28,29
The Beck Depression Inventory. The Beck Depression
Inventory (BDI)30 is a 21-item self-report questionnaire
designed to assess depressive symptoms. Higher total
scores reflect greater depressive symptomatology. The
BDI was administered at baseline, mid-treatment, end of
treatment, and 6 and 12 months post-treatment. The
BDI has good psychometric properties.31,32
Data Analysis
The analyses were based on the intent-to-treat princi-
ple, with missing data imputed with the last observation
carried forward. t-tests were used to compare partici-
pants receiving CBT-AN and SSCM on ratings of early,
middle, and late treatment therapeutic alliance. A
repeated-measures ANOVA was conducted to detect sig-
nificant change in therapeutic alliance over time. Hier-
archical multiple regressions were conducted to
investigate the predictive utility of therapeutic alliance
for weight change, depressive symptoms, and ED sever-
ity at end of treatment and follow-up. To test whether
early and late treatment therapeutic alliance had any
predictive value over and above the treatment received
and to adjust for the possible effect of early treatment
change, baseline values of outcome measures were
included in the first step of the hierarchical regressions,
with treatment assignment included in the second step,
and therapeutic alliance score included in the third step.
An alpha level of .05 was used to provide maximum
power to identify potential predictors of outcome.
Results
A total of 63 participants were randomly assigned
to CBT-AN (n 5 31) or SSCM (n 5 32). All study
participants were female and ranged in age from
20 to 61 years (M 5 33.4 6 9.6), with a range of
duration of illness of 7–49 years (M 5 16.6 6 8.5).
The mean BMI for the sample was 16.2 (SD 5 1.3,
range 5 11.8–18.5). The majority of participants
met criteria for AN restricting subtype (n 5 47,
74.6%). No significant differences on any baseline
characteristics were found between treatment
groups, sites, or group-by-site interactions.
No significant differences occurred between
CBT-AN participants and SSCM participants in
terms of therapeutic alliance ratings at Week 2
(t[61] 5 2.55, p 5 .59), mid-treatment (t[61] 5 .76,
p 5 .45), and end of treatment (t[61] 5 .08, p 5
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.94). A repeated-measures ANOVA indicated that
there were significant differences in HRQ scores
over the three time points in treatment (F[2, 124] 5
32.53, p < .001), as mid-treatment (SSCMM 5 20.8,
SD 5 7.8; CBT-AN M 5 19.1, SD 5 9.9) and end
of treatment (SSCM M 5 22.5, SD 5 9.9; CBT-AN
M 5 22.3, SD 5 9.0) therapeutic alliance scores
were significantly higher than the Week 2 scores
(SSCM M 5 13.4, SD 5 7.3; CBT-AN M 5 14.4, SD
5 6.4; p < .001).
Relationship between Therapeutic Alliance
and Clinical Outcomes
The results of hierarchical regressions evaluating
the relationship between the early and late thera-
peutic alliance and end of treatment and 12-month
follow-up outcomes are displayed in Tables 1 and
2. A detailed discussion on differences in outcome
by treatment is detailed elsewhere12; however, our
models indicated that Eating Concern at end of
treatment and Shape Concern at end of treatment
and follow-up were more strongly predicted by
CBT-AN (p < .04).
Early Treatment Therapeutic Alliance. Beyond the
effect of treatment, early therapeutic alliance
significantly predicted the Restraint subscale (b 5
2.26, SE 5 .03, p 5 .02) and Shape Concern sub-
scale (b 5 2.26, SE 5 .03, p 5 .008) at 12-month
follow-up. Early therapeutic alliance did not signifi-
cantly contribute to the models predicting BMI,
BDI, or EDE Global score outcomes at end of treat-
ment or 12-month follow-up (p >.05).
Late Treatment Therapeutic Alliance. Beyond the
effect of treatment, late therapeutic alliance signifi-
cantly predicted end of treatment BMI (b 5 .33, SE
5 .02, p < .001), BDI score (b 5 2.51, SE 5 .02, p <
.001), EDE Global score (b 5 2.31, SE 5 .01, p <
.001), and EDE subscales (ps < .004). Late thera-
peutic alliance also significantly predicted 12-
month follow-up BMI (b 5 .27, SE 5 .15, p 5 .005),
BDI score (b 5 2.30, SE 5 .18, p 5 .006), EDE
Global score (b 5 2.27, SE 5 .02, p 5 .003), and
EDE subscales (ps < .008), with the exception of
the model predicting the Eating Concern subscale
at 12-month follow-up (p 5 .07).
Discussion
This study aimed to examine the role of therapeu-
tic alliance in the outcome of two treatments for
TABLE 1. Hierarchical regressions of early therapeutic alliance predicting change in psychosocial and eating disorder
variables at end of treatment and follow-up
Hierarchical Regression Variable Step
End of Treatment 12-Month Follow-Up
df DR2 DF b p df DR2 DF b p
BMI model
BMI Baseline 1 1, 61 .539 71.19 0.734 <.001 1, 61 .432 46.42 0.657 <.001
Treatment group 2 2, 60 .007 .873 2.082 .35 2, 60 .006 .598 2.075 .44
HRQ total score 3 3, 59 .000 .055 2.021 .82 3, 59 .003 .003 .005 .96
BDI model
BDI Baseline 1 1, 61 .252 20.60 .502 <.001 1, 61 .250 20.29 .500 <.001
Treatment group 2 2, 60 .006 .475 .080 .49 2, 60 .001 .100 .037 .75
HRQ total score 3 3, 59 .002 .190 .050 .66 3, 59 .002 .128 2.041 .72
EDE Global Score model
EDE Global Baseline 1 1, 61 .530 68.68 .728 <.001 1, 61 .486 57.71 .697 <.001
Treatment group 2 2, 60 .012 1.56 2.110 .22 2, 60 .025 3.02 2.157 .09
HRQ total score 3 3, 59 .008 1.08 2.094 .30 3, 59 .018 2.92 2.139 .14
EDE Restraint model
EDE Restraint Baseline 1 1, 61 .090 6.04 .300 .02 1, 61 .145 10.38 .381 .002
Treatment group 2 2, 60 .044 .044 2.026 .84 2, 60 .026 1.91 2.163 .17
HRQ total score 3 3, 59 .053 3.65 2.232 .06 3, 59 .066 5.09 2.259 .02
EDE Eating Concern model
EDE Eating Concern Baseline 1 1, 61 .571 81.27 .756 <.001 1, 61 .478 55.81 .691 <.001
Treatment group 2 2, 60 .028 4.25 2.169 .04 2, 60 .010 1.22 2.103 .27
HRQ total score 3 3, 59 .000 .068 2.023 .80 3, 59 .003 .386 .061 .54
EDE Shape Concern model
EDE Shape Concern Baseline 1 1, 61 .452 50.36 .672 <.001 1, 61 .378 37.07 .615 <.001
Treatment group 2 2, 60 .036 4.24 2.190 .04 2, 60 .049 5.15 2.222 .03
HRQ total score 3 3, 59 .017 1.97 2.130 .17 3, 59 .065 7.50 2.257 .008
EDE Weight Concern model
EDE Weight Concern Baseline 1 1, 61 .488 58.12 .698 <.001 1, 61 .459 51.80 .678 <.001
Treatment group 2 2, 60 .019 2.31 2.138 .13 2, 60 .018 2.10 2.135 .15
HRQ total score 3 3, 59 .003 .321 2.053 .57 3, 59 .019 2.27 2.142 .14
Note: Step 1 examines the main effect of baseline score. Step 2 examines the main effect of treatment type. Step 3 examines the main effect of therapeu-
tic alliance score. BMI, body mass index; BDI, Beck Depression Inventory; HRQ, Helping Relationship Questionnaire; EDE, Eating Disorders Examination.
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adults with SE-AN. Early, mid, and late treatment
therapeutic alliance was present, with no signifi-
cant differences in patient ratings across treatment
types. Adjusting for early treatment change and
type of treatment, early treatment therapeutic alli-
ance predicted treatment outcome in terms of
Restraint and Shape Concern in follow-up, but not
changes in other ED domains, depressive symp-
tomatology, or weight. Late therapeutic alliance
predicted treatment and follow-up outcomes for all
evaluated domains, with the exception of Eating
Concern at follow-up.
Consistent with our hypothesis, there were no
significant differences in patient ratings of thera-
peutic alliance of the two treatments. Although
CBT-AN and SSCM use unique intervention strat-
egies to achieve therapy aims, both were able to
promote moderate therapeutic alliance in early
treatment, increasing to strong therapeutic alliance
in late treatment, to relatively the same degree. The
level of therapeutic alliance is also consistent with
the use of the HRQ with other ED samples.18
Consistent with our hypothesis, therapeutic alli-
ance was a predictor of some ED symptomatology.
Specifically, Restraint and Shape Concern subscale
scores at follow-up were significantly predicted by
early treatment therapeutic alliance, beyond the
effect of baseline severity and treatment assign-
ment. With the exception of Shape Concern at
follow-up, all ED and depressive symptomatology
assessed at end of treatment and follow-up were
significantly predicted by late treatment therapeu-
tic alliance. These findings may indicate that
although early treatment therapeutic alliance is
present for patients with SE-AN, the possible bene-
fits of the therapeutic relationship to treatment
outcome require more time to develop. More
research is required to better understand how ther-
apeutic alliance interacts with both treatment
interventions to enact change in specific ED symp-
tomatology, both during treatment and post-
treatment.
Depressive symptomatology and changes in
weight were not significantly predicted by early
treatment therapeutic alliance for either treatment,
but were predicted by late treatment therapeutic
alliance. Although speculative, the failure of early
therapeutic alliance to predict changes in weight
and depressive symptoms may arise from the fact
that changes in these domains are more resistant
to change. As previously postulated, it is possible
that such variables require a longer exposure to the
TABLE 2. Hierarchical regressions of late therapeutic alliance predicting change in psychosocial and eating disorder
variables at end of treatment and follow-up
Hierarchical Regression Variable Step
End of Treatment 12-Month Follow-Up
df DR2 DF b p df DR2 DF b p
BMI model
BMI Baseline 1 1, 61 .539 71.19 .734 <.001 1, 61 .432 46.42 .657 <.001
Treatment group 2 2, 60 .007 .873 2.082 .35 2, 60 .006 .598 2.075 .44
HRQ total score 3 3, 59 .101 16.91 .325 <.001 3, 59 .072 8.72 .274 .005
BDI model
BDI Baseline 1 1, 61 .252 20.60 .502 <.001 1, 61 .250 20.29 .500 <.001
Treatment group 2 2, 60 .006 .475 .080 .49 2, 60 .001 .100 .037 .753
HRQ total score 3 3, 59 .260 31.89 2.512 <.001 3, 59 .092 8.23 2.304 .006
EDE Global Score model
EDE Global Baseline 1 1, 61 .530 68.68 .728 <.001 1, 61 .486 57.71 .697 <.001
Treatment group 2 2, 60 .012 1.57 2.110 .22 2, 60 .025 3.02 2.157 .09
HRQ total score 3 3, 59 .095 15.36 2.310 <.001 3, 59 .070 9.85 2.267 .003
EDE Restraint model
EDE Restraint Baseline 1 1, 61 .090 6.04 .300 .02 1, 61 .145 10.38 .381 .002
Treatment group 2 2, 60 .001 .044 2.026 .84 2, 60 .026 1.91 2.163 .17
HRQ total score 3 3, 59 .175 14.05 2.419 <.001 3, 59 .093 7.46 2.305 .008
EDE Eating Concern model
EDE Eating Concern Baseline 1 1, 61 .571 81.27 .756 <.001 1, 61 .478 55.81 .691 <.001
Treatment group 2 2, 60 .028 4.25 2.169 .04 2, 60 .010 1.22 2.103 .27
HRQ total score 3 3, 59 .096 18.50 2.313 <.001 3, 59 .029 3.49 2.171 .07
EDE Shape Concern model
EDE Shape Concern Baseline 1 1, 61 .452 50.34 .672 <.001 1, 61 .378 37.07 .615 <.001
Treatment group 2 2, 60 .036 4.24 2.190 .04 2, 60 .049 5.15 2.222 .03
HRQ total score 3 3, 59 .068 9.06 2.261 .004 3, 59 .092 11.24 2.303 .001
EDE Weight Concern model
EDE Weight Concern Baseline 1 1, 61 .488 58.12 .698 <.001 1, 61 .459 51.80 .678 <.001
Treatment group 2 2, 60 .019 2.31 2.138 .13 2, 60 .018 2.10 2.135 .15
HRQ total score 3 3, 59 .090 13.19 2.303 .001 3, 59 .076 9.98 2.278 .003
Note: Step 1 examines the main effect of baseline score. Step 2 examines the main effect of treatment type. Step 3 examines the main effect of therapeu-
tic alliance score. BMI, body mass index; BDI, Beck Depression Inventory; HRQ, Helping Relationship Questionnaire; EDE, Eating Disorders Examination.
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therapeutic relationship before positive change
may be predicted. Future research should examine
factors that affect these outcomes.
To our knowledge, this is the first study to exam-
ine the predictive role of therapeutic alliance in the
outcome of two treatments for adults with SE-AN.
Understanding the factors that promote positive
treatment outcomes and improve retention pro-
vides greater insights on how to most effectively
intervene for this population. There were several
strengths to this study, specifically the strongest
retention rate to our knowledge of a study of adults
with AN, assessments with well-validated meas-
ures, and 12-month follow-up data. Yet limitations
also warrant acknowledgement. Our sample sizes
were moderate, yet sufficient to show differences
in outcomes. It is of note that the number of analy-
ses conducted increases the risk for Type I error.
Finally, as the majority of the sample met criteria
for restricting subtype, we were unable to explore
the effect of therapeutic alliance on bingeing and
purging outcomes for the SE-AN population.
Future studies should explore the role of therapeu-
tic alliance in the treatment of adults with SE-AN in
larger samples.
In summary, consistent with previous findings
from ED samples, therapeutic alliance can effec-
tively be established in adults with SE-AN, with no
significant differences occurring between those
treated with CBT-AN and SSCM. Early therapeutic
alliance significantly predicted some ED symptom-
atology, but not changes in weight or depression.
Late therapeutic alliance predicted all ED and
depressive symptoms, with the exception of Shape
Concern at follow-up. Future research should
examine other aspects of interventions that posi-
tively affect retention and outcome for adults with
SE-AN.
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